Alpha Hydroxybutyric Acid
Alpha hydroxybutyric acid (AHB) is an organic acid and a metabolic intermediate involved in several biochemical pathways within the human body. Its presence and concentration in biological fluids, such as blood serum, can reflect various aspects of an individual’s metabolic health. The of AHB levels has gained attention as a potential biomarker for assessing metabolic status and identifying risks for certain health conditions.
Biological Basis
Section titled “Biological Basis”Alpha hydroxybutyric acid is primarily formed during the catabolism (breakdown) of certain amino acids, particularly methionine and threonine. It can also be produced when there is an imbalance in fatty acid metabolism or an increase in oxidative stress. The pathways involving AHB are intricate and interconnected with glucose and lipid metabolism, suggesting its role as a marker that integrates information from multiple metabolic processes. Elevated levels of AHB can indicate shifts in these metabolic pathways, often reflecting a cellular response to stress or changes in nutrient utilization.
Clinical Relevance
Section titled “Clinical Relevance”The clinical significance of alpha hydroxybutyric acid lies in its association with metabolic disorders. Research has indicated that elevated AHB levels can serve as an early indicator of insulin resistance and impaired glucose tolerance, conditions that often precede the development of type 2 diabetes. As such, measuring AHB could potentially aid in the early detection of individuals at risk, allowing for timely interventions. It may also provide insights into the progression of metabolic dysfunction, making it a valuable tool in monitoring metabolic health.
Social Importance
Section titled “Social Importance”Given the global rise in the prevalence of metabolic syndrome, obesity, and type 2 diabetes, biomarkers like alpha hydroxybutyric acid hold considerable social importance. Early identification of metabolic abnormalities through AHB could facilitate preventive strategies, personalized dietary and lifestyle interventions, and targeted medical management. By providing a clearer picture of an individual’s metabolic state, AHB analysis contributes to public health efforts aimed at reducing the burden of chronic metabolic diseases and improving overall population health outcomes.
Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Research into traits like alpha hydroxybutyric acid is often constrained by the inherent design and statistical power of genome-wide association studies (GWAS). While meta-analyses combine data from multiple cohorts to enhance statistical power, heterogeneity can arise due to study-specific criteria for genotyping quality control and analytical approaches ;.[1] GCKRregulates the activity of glucokinase, a critical enzyme in glucose metabolism within the liver and pancreas.[2] Alterations in GCKR function, such as those caused by rs1260326 , can lead to changes in hepatic glucose uptake and triglyceride synthesis, processes that are fundamental to insulin sensitivity and thus can influence alpha hydroxybutyric acid levels.
Other variants affect genes involved in diverse cellular functions that indirectly contribute to metabolic regulation. For instance, the ATP-binding cassette subfamily C member 4 gene (ABCC4) encodes a transporter protein responsible for moving various substances, including hormones and metabolites, across cell membranes. Variations like rs11620327 in ABCC4 could alter the efficiency of these transport processes, thereby affecting the cellular environment and overall metabolic homeostasis.[3] Similarly, long non-coding RNAs like GTF3C2-AS2 (variant rs7586601 ) can regulate the expression of other genes, including those involved in glucose and lipid metabolism, influencing cellular responses to metabolic cues . Genes such asNOSTRIN and SPC25 (associated with rs11676084 ) play roles in cellular trafficking and cytoskeletal organization, which, when perturbed by genetic variation, can have downstream effects on cell signaling and metabolic function.
Further genetic influences on metabolic health come from variants like rs5916060 in the region of HADHBP1 and LINC03070, and rs6662888 affecting KLF17 and KLF18. HADHBP1 is a pseudogene related to hydroxyacyl-CoA dehydrogenase, an enzyme crucial for fatty acid oxidation, while LINC03070 is a long intergenic non-coding RNA that may regulate metabolic pathways.[4] The KLF genes, KLF17 and KLF18, belong to a family of transcription factors that regulate gene expression involved in lipid and glucose homeostasis. Variants in these genes can modulate the intricate balance of metabolic processes, affecting how the body handles nutrients and energy.[5] Finally, rs10844446 , found near ASS1P14 and SYT10, could also contribute to variations in metabolic profiles. ASS1P14is a pseudogene related to the urea cycle, impacting amino acid metabolism, whileSYT10is involved in vesicle trafficking, which is critical for hormone secretion and cellular communication relevant to metabolic regulation.[6]These genetic variations collectively highlight the complex interplay of diverse cellular mechanisms that contribute to an individual’s metabolic state and, consequently, their alpha hydroxybutyric acid levels.
Clinical Context and Initial Biomarker Evaluation
Section titled “Clinical Context and Initial Biomarker Evaluation”The diagnostic process for metabolic markers, such as alpha hydroxybutyric acid, often begins with a thorough clinical assessment to evaluate the patient’s symptoms, medical history, and any relevant risk factors. Biomarker measurements are employed to identify underlying conditions, monitor disease progression, assess treatment efficacy, or detect adverse drug effects. For instance, liver enzyme tests like gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and aspartate aminotransferase (AST) are routinely used to diagnose liver diseases, track their severity, and identify drug-induced liver injury.[4]Beyond hepatic function, these markers also hold epidemiological significance as indicators for conditions such as type 2 diabetes, cardiovascular disease, and overall mortality.[4]Interpreting biomarker levels requires careful consideration of demographic factors and potential co-morbidities, with studies often adjusting for age, sex, smoking status, body mass index, blood pressure, cholesterol levels, glucose, diabetes, and alcohol intake to ensure clinical accuracy.[3]
Advanced Laboratory and Molecular Assays
Section titled “Advanced Laboratory and Molecular Assays”Accurate of metabolic biomarkers relies on sophisticated laboratory techniques. Targeted metabolite profiling is frequently performed using electrospray ionization (ESI) tandem mass spectrometry (MS/MS) on quantitative metabolomics platforms, enabling the simultaneous quantification of various metabolites, including fatty acid derivatives, from serum samples.[7] This technique, which involves rapid sample preparation, is crucial for comprehensive metabolic analysis.[7] Other biochemical assays utilize methods such as spectrophotometry for gamma-glutamyl aminotransferase and colorimetric methods for bilirubin quantification.[3] The reproducibility of these assays is vital for diagnostic reliability, with reported intra-assay coefficients of variation ranging from approximately 2.3% to 8.8% for various inflammatory and natriuretic markers, and inter-assay coefficients of variation between 10% and 15.2% for certain vitamins and peptides.[3] Molecular diagnostics, including genetic testing, also play a role in identifying underlying causes of metabolic imbalances. For example, analysis of ACADM genotypes is correlated with biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency, a disorder affecting fatty acid metabolism.[8] Genetic factors significantly influence biomarker levels, with heritabilities for liver enzymes such as ALT and GGT estimated to be substantial.[4]
Screening and Differential Diagnostic Approaches
Section titled “Screening and Differential Diagnostic Approaches”Screening programs are essential for early detection of metabolic disorders, particularly in vulnerable populations. Newborn screening, for instance, can identify conditions like medium-chain acyl-CoA dehydrogenase deficiency by correlating specific ACADM genotypes with corresponding biochemical phenotypes.[8]The interpretation of biomarker results often involves differential diagnosis, distinguishing the measured levels from those associated with similar conditions or physiological variations. For example, specific patterns in alkaline phosphatase levels may indicate underlying bone or intestinal conditions, guiding further diagnostic steps.[4] However, diagnostic challenges can arise due to variations in biomarker levels across different populations, which may be attributed to demographic differences and methodological discrepancies in assay techniques.[4] Therefore, standardized protocols and careful consideration of individual clinical context are paramount to avoid misdiagnosis and ensure appropriate patient management.
Metabolic Processes and Key Biomolecules
Section titled “Metabolic Processes and Key Biomolecules”Metabolomics research aims to comprehensively measure endogenous metabolites within biological fluids, providing a functional readout of the body’s physiological state.[7] These metabolites are integral to various cellular functions and are often modulated by the activity of specific enzymes and proteins. For instance, the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is a critical biomolecule in the mevalonate pathway, which is essential for cholesterol synthesis.[9] Similarly, the enzyme medium-chain acyl-CoA dehydrogenase, encoded by the ACADM gene, plays a vital role in fatty acid metabolism.[10]Other key biomolecules, such as liver enzymes including alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and alanine-aminotransferase (ALT), are also routinely measured as biomarkers reflecting metabolic health.[3]
Genetic Regulation of Metabolite Levels
Section titled “Genetic Regulation of Metabolite Levels”Genetic mechanisms profoundly influence the homeostasis of various endogenous metabolites. Genetic variants, such as single nucleotide polymorphisms (SNPs), can directly impact metabolite concentrations by altering gene functions, regulatory elements, or gene expression patterns.[7] For example, common SNPs in the HMGCR gene have been shown to affect the alternative splicing of exon 13, which in turn influences LDL-cholesterol levels.[9] This demonstrates how genetic variations can modify protein structure and function, leading to changes in metabolic pathways. Moreover, variations in the ABO gene, which determines ABO blood groups, are associated with plasma ALP levels, highlighting a genetic influence on enzyme activity and systemic metabolism.[11] The HNF1Agene, encoding hepatocyte nuclear factor-1 alpha, also exhibits polymorphisms that are associated with C-reactive protein and GGT levels, indicating its role in broader transcriptional regulation of metabolic processes.[12]
Cellular Functions and Homeostatic Control
Section titled “Cellular Functions and Homeostatic Control”The intricate balance of metabolite levels within the body is maintained through complex cellular functions and regulatory networks. Cellular processes like alternative splicing, where specific exons are included or excluded from messenger RNA, can alter the final protein product and its activity, as seen with HMGCR and its impact on cholesterol metabolism.[9] Beyond splicing, the degradation rate of enzymes, such as 3-hydroxy-3-methylglutaryl-CoA reductase, also influences its steady-state levels and, consequently, the metabolic flux through its pathway.[13] These regulatory mechanisms ensure that metabolite concentrations remain within a healthy range, and disruptions in these homeostatic controls can signal underlying physiological imbalances.[7]
Systemic Consequences and Pathophysiological Relevance
Section titled “Systemic Consequences and Pathophysiological Relevance”Dysregulation of metabolite levels often has systemic consequences and can be indicative of various pathophysiological processes. Plasma levels of liver enzymes, such as ALT, GGT, and ALP, are widely used in clinical diagnostics not only for identifying liver diseases but also as prospective risk factors for conditions like type 2 diabetes, cardiovascular disease, and increased mortality.[4] The association between ABOblood group and ALP levels, for instance, may involve genetically determined variations in the proportion of ALP isoenzymes or the appearance of intestinal ALP in plasma after fatty meals, illustrating the interplay between genetics, diet, and organ-specific responses.[14] Furthermore, conditions like medium-chain acyl-CoA dehydrogenase deficiency, caused by mutations in the ACADM gene, exemplify how specific genetic defects in fatty acid metabolism can lead to significant health impairments, underscoring the critical role of metabolite homeostasis in overall health.[8]
Regulation of Lipid and Sterol Biosynthesis
Section titled “Regulation of Lipid and Sterol Biosynthesis”The synthesis of cholesterol, a critical sterol, is intricately controlled through the mevalonate pathway, with 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) serving as a key regulatory enzyme.[15] Its activity is modulated by various mechanisms, including the oligomerization state of the enzyme, which influences its degradation rate.[13]Genetic variations, such as common single nucleotide polymorphisms (SNPs) inHMGCR, can impact LDL-cholesterol levels by affecting alternative splicing of exon 13, thereby altering the enzyme’s expression or function.[9] Beyond HMGCR, alternative splicing also plays a crucial role in regulating other lipid-related proteins, such as apolipoprotein B (APOB), where antisense oligonucleotides can induce novel APOB isoforms.[16]These regulatory layers, from gene expression to protein modification and splicing, collectively maintain lipid homeostasis, with dysregulation contributing to conditions like dyslipidemia and increased risk of coronary artery disease.[1], [17]
Fatty Acid Metabolism and Hepatic Homeostasis
Section titled “Fatty Acid Metabolism and Hepatic Homeostasis”Fatty acid metabolism involves a complex network of enzymatic processes for synthesis, breakdown, and modification. The FADS1 and FADS2 gene cluster, for instance, encodes desaturases essential for determining the composition of polyunsaturated fatty acids in phospholipids, with specific genetic variants and haplotypes influencing these profiles.[18] Proper mitochondrial beta-oxidation is vital for fatty acid breakdown, and genetic variations in genes like ACADM, associated with medium-chain acyl-CoA dehydrogenase deficiency, can lead to distinct biochemical phenotypes.[8]Furthermore, the balance of fatty acid metabolites, including prostaglandins and lipoxygenase-derived compounds, reflects dynamic metabolic states.[19]Disruptions in these pathways can manifest as conditions such as nonalcoholic fatty liver disease, where enzymes like glycosylphosphatidylinositol-specific phospholipase D may play a role.[20]
Uric Acid Transport and Renal Regulation
Section titled “Uric Acid Transport and Renal Regulation”The maintenance of uric acid levels in the blood is primarily governed by renal transport mechanisms, involving specific transporters like the urate anion exchanger.[21] The SLC2A9 gene, also known as GLUT9, encodes a facilitative glucose transporter family member that significantly influences serum uric acid concentrations, urate excretion, and susceptibility to gout.[5], [22], [23] This transporter exhibits alternative splicing, leading to different isoforms that may affect its trafficking and function.[24] Genetic variants in SLC2A9have been consistently associated with uric acid levels, often showing sex-specific effects.[25] The interplay between SLC2A9and fructose metabolism further highlights a systems-level integration, as fructose intake can impact urate levels.[5], [23]
Immune Response, Cellular Adhesion, and Systemic Regulation
Section titled “Immune Response, Cellular Adhesion, and Systemic Regulation”Cellular adhesion and immune responses are mediated by specific molecular interactions and signaling cascades. For example, the ABO histo-blood group antigens are covalently linked to proteins like soluble intercellular adhesion molecule-1 (ICAM-1), influencing their function.[26] The expression of ICAM-1 itself is transcriptionally regulated by inflammatory cytokines, often involving a variant NF-kappa B site and p65 homodimers, highlighting a crucial signaling pathway in inflammation.[27]Other regulatory mechanisms include protein interactions with nuclear receptors, such as the thyroid hormone receptor, which can depend on the presence or absence of specific hormones.[28] At a broader systemic level, enzymes like glutathione S-transferase omega 1 and 2 are involved in detoxification and can influence systemic inflammation.[29] Genetic factors, such as polymorphisms in HNF1A, also contribute to systemic inflammatory markers like C-reactive protein, demonstrating the interconnectedness of metabolic and immune pathways.[4]
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs1260326 | GCKR | urate total blood protein serum albumin amount coronary artery calcification lipid |
| rs11676084 | NOSTRIN, SPC25 | alpha-hydroxybutyric acid beta-hydroxybutyric acid sexual dimorphism |
| rs11620327 | ABCC4 | alpha-hydroxybutyric acid |
| rs7586601 | GTF3C2-AS2 | lactate alpha-hydroxybutyric acid diabetes mellitus |
| rs5916060 | HADHBP1 - LINC03070 | alpha-hydroxybutyric acid |
| rs6662888 | KLF17 - KLF18 | alpha-hydroxybutyric acid |
| rs10844446 | ASS1P14 - SYT10 | alpha-hydroxybutyric acid |
Frequently Asked Questions About Alpha Hydroxybutyric Acid
Section titled “Frequently Asked Questions About Alpha Hydroxybutyric Acid”These questions address the most important and specific aspects of alpha hydroxybutyric acid based on current genetic research.
1. Does my ethnic background affect my AHB levels or risk?
Section titled “1. Does my ethnic background affect my AHB levels or risk?”Yes, it can. Research shows that most studies on AHB levels have focused on people of European ancestry, meaning the findings might not fully apply to other ethnic groups. Differences in genetic makeup, lifestyle, and environmental factors across populations can influence AHB levels and your personal risk. It highlights the need for more diverse studies to understand these variations better.
2. If I’m trying to prevent diabetes, how useful is an AHB test for me?
Section titled “2. If I’m trying to prevent diabetes, how useful is an AHB test for me?”An AHB test can be very useful for prevention. Elevated AHB levels can serve as an early indicator of insulin resistance and impaired glucose tolerance, conditions that often precede type 2 diabetes. Knowing your AHB levels early can help guide personalized dietary and lifestyle interventions, potentially delaying or preventing the onset of diabetes.
3. My sibling is healthy, but I’m worried about my metabolism; can an AHB test explain why we’re different?
Section titled “3. My sibling is healthy, but I’m worried about my metabolism; can an AHB test explain why we’re different?”An AHB test can offer insights, but it’s complex. While genetic factors play a role in AHB levels, many other elements contribute, including lifestyle, diet, and unique environmental exposures. These gene-environment interactions, along with numerous genetic variants with small effects, mean that even siblings can have different metabolic profiles and AHB levels.
4. Can changing my diet really lower my AHB levels?
Section titled “4. Can changing my diet really lower my AHB levels?”Yes, your diet can significantly influence your AHB levels. AHB is connected to glucose and lipid metabolism, and its levels can reflect shifts in nutrient utilization. Personalized dietary interventions, as part of a broader lifestyle change, are crucial for managing metabolic health and can help bring elevated AHB levels back into a healthy range.
5. Does stress or poor sleep actually raise my AHB levels?
Section titled “5. Does stress or poor sleep actually raise my AHB levels?”Yes, lifestyle factors like stress and potentially poor sleep can influence your AHB levels. AHB can be produced when there’s an increase in oxidative stress, which can be exacerbated by chronic stress. These environmental factors interact with your genetic predispositions, impacting your overall metabolic health and biomarker levels.
6. If I exercise regularly, why might my AHB still be high?
Section titled “6. If I exercise regularly, why might my AHB still be high?”Even with regular exercise, your AHB levels could be high due to a combination of factors. While exercise is beneficial, genetic predispositions play a significant role in metabolic regulation. Other contributors like diet, underlying metabolic imbalances, or even oxidative stress not fully mitigated by exercise can keep AHB levels elevated, highlighting the complexity of metabolic health.
7. Could an AHB test result vary depending on where I get it done?
Section titled “7. Could an AHB test result vary depending on where I get it done?”Yes, it’s possible. Differences in how AHB levels are measured, including specific analytical techniques and laboratory protocols, can introduce variability in results between different studies or testing facilities. This is a known limitation in research and can affect the comparability of findings, even among similar populations.
8. What can an AHB test tell me specifically about my metabolism?
Section titled “8. What can an AHB test tell me specifically about my metabolism?”An AHB test can give you a clearer picture of your individual metabolic state. It reflects how your body is processing amino acids, fats, and glucose, and can indicate cellular responses to stress or nutrient changes. This information can be valuable for understanding your personal risk for metabolic disorders and guiding targeted health strategies.
9. Is an AHB test better than blood sugar for early diabetes warning?
Section titled “9. Is an AHB test better than blood sugar for early diabetes warning?”An AHB test offers a complementary and potentially earlier warning than standard blood sugar tests. Elevated AHB levels can be an early indicator of insulin resistance and impaired glucose tolerance, often appearing before overt signs of type 2 diabetes. It provides insights into metabolic dysfunction that might not be immediately apparent from glucose levels alone.
10. If diabetes runs in my family, can AHB tell me my personal risk?
Section titled “10. If diabetes runs in my family, can AHB tell me my personal risk?”Yes, an AHB test can provide valuable insight into your personal risk, especially with a family history of diabetes. Since AHB levels can indicate early signs of insulin resistance, it can help identify if you are metabolically predisposed even before symptoms appear. This allows for proactive measures to mitigate your inherited risk.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Willer CJ. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40(2):161-169.
[2] Saxena R. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316(5829):1331-1336.
[3] Benjamin EJ, et al. “Genome-Wide Association with Select Biomarker Traits in the Framingham Heart Study.” BMC Medical Genetics, vol. 8, 2007, p. 77.
[4] Yuan X, et al. “Population-Based Genome-Wide Association Studies Reveal Six Loci Influencing Plasma Levels of Liver Enzymes.” American Journal of Human Genetics, vol. 83, no. 4, 2008, pp. 520-528.
[5] McArdle PF. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. Arthritis Rheum. 2008;58(9):2874-2881.
[6] Dehghan A. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372(9654):1959-1965.
[7] Gieger C, et al. “Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum.”PLoS Genetics, vol. 4, no. 11, 2008, p. e1000282.
[8] Maier EM, et al. “Population Spectrum of ACADM Genotypes Correlated to Biochemical Phenotypes in Newborn Screening for Medium-Chain Acyl-CoA Dehydrogenase Deficiency.” Human Mutation, vol. 25, no. 5, 2005, pp. 443-452.
[9] Burkhardt R, et al. “Common SNPs in HMGCR in Micronesians and Whites Associated with LDL-Cholesterol Levels Affect Alternative Splicing of Exon13.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 11, 2008, pp. 2078-2085.
[10] Caspi A, et al. “Moderation of Breastfeeding Effects on the IQ by Genetic Variation in Fatty Acid Metabolism.” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, 2007, pp. 18860-18865.
[11] Melzer D, et al. “A Genome-Wide Association Study Identifies Protein Quantitative Trait Loci (pQTLs).” PLoS Genetics, vol. 4, no. 5, 2008, p. e1000072.
[12] Rieder MJ, et al. “Polymorphisms of the HNF1A Gene Encoding Hepatocyte Nuclear Factor-1 Alpha Are Associated with C-Reactive Protein.”American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1193-1201.
[13] Cheng HH, et al. “Oligomerization State Influences the Degradation Rate of 3-Hydroxy-3-Methylglutaryl-CoA Reductase.” Journal of Biological Chemistry, vol. 274, no. 24, 1999, pp. 17171-17178.
[14] Whitfield JB, Martin NG. “Determinants of Variation in Plasma Alkaline Phosphatase Activity: A Twin Study.”American Journal of Human Genetics, vol. 35, no. 5, 1983, pp. 978-986.
[15] Goldstein JL, Brown MS. “Regulation of the Mevalonate Pathway.” Nature, vol. 343, no. 6257, 1990, pp. 425-430.
[16] Khoo B, et al. “Antisense Oligonucleotide-Induced Alternative Splicing of the APOB mRNA Generates a Novel Isoform of APOB.” BMC Molecular Biology, vol. 8, no. 1, 2007, p. 3.
[17] Kathiresan S. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2008;40(12):1428-1437.
[18] Schaeffer, L., et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet, vol. 15, no. 10, 2006, pp. 1745–1756.
[19] Unterwurzacher, I., et al. “Rapid sample preparation and simultaneous quantitation of free prostaglandins and lipoxygenase derived fatty acid metabolites by LC-MS/MS from small.”Anal Bioanal Chem, 2008.
[20] Chalasani N, et al. “Glycosylphosphatidylinositol-Specific Phospholipase D in Nonalcoholic Fatty Liver Disease: A Preliminary Study.”Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 6, 2006, pp. 2279-2285.
[21] Anzai, N., et al. “New insights into renal transport of urate.”Curr Opin Rheumatol, vol. 19, no. 2, 2007, pp. 151–157.
[22] Li, S., et al. “The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts.”PLoS Genet, vol. 3, no. 11, 2007, p. e194.
[23] Vitart, V., et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.”Nat Genet, vol. 40, no. 4, 2008, pp. 437–442.
[24] Augustin, R., et al. “Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking.”J Biol Chem, vol. 279, no. 16, 2004, pp. 16229–16236.
[25] Döring, A., et al. “SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.”Nat Genet, vol. 40, no. 4, 2008, pp. 430–436.
[26] Pare, G., et al. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genet, vol. 4, no. 7, 2008, p. e1000118.
[27] Ledebur, H.C., and T.P. Parks. “Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers.” J Biol Chem, vol. 270, no. 2, 1995, pp. 933–943.
[28] Lee JW, et al. “Two Classes of Proteins Dependent on Either the Presence or Absence of Thyroid Hormone for Interaction with the Thyroid Hormone Receptor.”Molecular Endocrinology, vol. 9, no. 2, 1995, pp. 243-254.
[29] Wilk, J.B., et al. “Framingham Heart Study genome-wide association: results for pulmonary function measures.” BMC Med Genet, vol. 8, 2007, p. 58.